Skip to main content
Erschienen in: Uro-News 4/2018

02.04.2018 | Erektile Dysfunktion | Zertifizierte Fortbildung

Individuelle und multimodale Therapie nach Stufenschema

Erektile Dysfunktion — Update 2018

verfasst von: PD Dr. med. Matthias Trottmann

Erschienen in: Uro-News | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Schätzungen zufolge leiden sechs bis acht Millionen Männer in Deutschland unter einer Erektionsstörung. Auf eine individualisierte Diagnostik sollte eine Stufentherapie folgen. Multimodal umgesetzt führt diese zu einer hohen Ansprechrate.
Literatur
1.
Zurück zum Zitat Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res. 2000; 12(6):305–11.CrossRefPubMed Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res. 2000; 12(6):305–11.CrossRefPubMed
2.
Zurück zum Zitat May M, Gralla O, Knoll N, et al. Erectile dysfunction, discrepancy between high prevalence and low utilization of treatment options: Results from the Cottbus Survey with 10.000 men. BJU Inter. 2007; 100(5): 1110–5. May M, Gralla O, Knoll N, et al. Erectile dysfunction, discrepancy between high prevalence and low utilization of treatment options: Results from the Cottbus Survey with 10.000 men. BJU Inter. 2007; 100(5): 1110–5.
4.
Zurück zum Zitat Montorsi P, Ravagnani PM, Galli, S et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005; 96(12B): 19M–23M.CrossRefPubMed Montorsi P, Ravagnani PM, Galli, S et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005; 96(12B): 19M–23M.CrossRefPubMed
5.
Zurück zum Zitat Guo W, Liao C, Zou Y, et al. Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies. J Sex Med. 2010; 7: 2805–16.CrossRefPubMed Guo W, Liao C, Zou Y, et al. Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies. J Sex Med. 2010; 7: 2805–16.CrossRefPubMed
6.
Zurück zum Zitat Miner M, Nehra A, Jackson G, et al. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med. 2014; 127(3): 174–82.CrossRefPubMed Miner M, Nehra A, Jackson G, et al. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med. 2014; 127(3): 174–82.CrossRefPubMed
7.
Zurück zum Zitat Trottmann M, Becker AJ. Andrologie. In: Hegele A, Skrobek L (Hrsg.). Essentials Intensivkurs zur Weiterbildung — Urologie. 1. Aufl. Georg Thieme Verlag KG; 2015. Trottmann M, Becker AJ. Andrologie. In: Hegele A, Skrobek L (Hrsg.). Essentials Intensivkurs zur Weiterbildung — Urologie. 1. Aufl. Georg Thieme Verlag KG; 2015.
8.
Zurück zum Zitat Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999; 11(6): 319–26.CrossRefPubMed Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999; 11(6): 319–26.CrossRefPubMed
10.
Zurück zum Zitat Rosen RC, Marin H. Prevalence of antidepressant-associated erectile dysfunction. J Clin Psychiatry. 2003; 64 Suppl 10: 5–10.PubMed Rosen RC, Marin H. Prevalence of antidepressant-associated erectile dysfunction. J Clin Psychiatry. 2003; 64 Suppl 10: 5–10.PubMed
11.
Zurück zum Zitat Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013; 10(1): 130–71.CrossRefPubMed Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013; 10(1): 130–71.CrossRefPubMed
12.
Zurück zum Zitat Reisman Y, Porst H, Lowenstein L, et al. The ESSM Manual of Sexual Medicine. 2. Auf. Amsterdam: Medix Publishers; 2015. Reisman Y, Porst H, Lowenstein L, et al. The ESSM Manual of Sexual Medicine. 2. Auf. Amsterdam: Medix Publishers; 2015.
14.
Zurück zum Zitat La Vignera S, Condorelli S, Vicari E, et al. Physical activity and erectile dysfunction in middle-aged men: a brief review. J Andrology 2012; 33(2): 154–61.CrossRef La Vignera S, Condorelli S, Vicari E, et al. Physical activity and erectile dysfunction in middle-aged men: a brief review. J Andrology 2012; 33(2): 154–61.CrossRef
15.
Zurück zum Zitat Cheetham TC, Van Den Eeden SK, Jacobsen SJ. Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look to Additional Parameters. JAMA Intern Med. 2017; 177(9): 1393–4.CrossRefPubMed Cheetham TC, Van Den Eeden SK, Jacobsen SJ. Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look to Additional Parameters. JAMA Intern Med. 2017; 177(9): 1393–4.CrossRefPubMed
16.
Zurück zum Zitat Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol. 2017; 72(6): 1000–11.CrossRefPubMed Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol. 2017; 72(6): 1000–11.CrossRefPubMed
17.
Zurück zum Zitat Trottmann M, Marcon J, Pompe S, et al. [Conservative therapy of erectile dysfunction]. Urologe A 2015; 54 (5): 668–75.CrossRefPubMed Trottmann M, Marcon J, Pompe S, et al. [Conservative therapy of erectile dysfunction]. Urologe A 2015; 54 (5): 668–75.CrossRefPubMed
18.
Zurück zum Zitat Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol. 2004; 45: 339–45.CrossRefPubMed Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol. 2004; 45: 339–45.CrossRefPubMed
19.
Zurück zum Zitat Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009; 51(9): 650–61.CrossRef Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009; 51(9): 650–61.CrossRef
20.
Zurück zum Zitat Yafi FA, Sharlip ID, Becher EF. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. Sex Med Rev. 2017; https://doi.org/10.1016/j.sxmr.2017.08.001. Yafi FA, Sharlip ID, Becher EF. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. Sex Med Rev. 2017; https://​doi.​org/​10.​1016/​j.​sxmr.​2017.​08.​001.​
21.
Zurück zum Zitat Vernet D, Magee T, Qian A, et al. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med. 2006; 3(1): 84–94.CrossRefPubMed Vernet D, Magee T, Qian A, et al. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med. 2006; 3(1): 84–94.CrossRefPubMed
22.
Zurück zum Zitat McMurray JG, Feldman RA, Auerbach SM, et al. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag. 2007; 3(6): 975–81.PubMedPubMedCentral McMurray JG, Feldman RA, Auerbach SM, et al. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag. 2007; 3(6): 975–81.PubMedPubMedCentral
24.
Zurück zum Zitat Romero Otero J, García Gómez B, Medina Polo J, et al. Evaluation of current errors within the administration of phosphodiesterase-5 inhibitors after more than 10 years of use. Urology 2014; 83(6): 1334–8.CrossRefPubMed Romero Otero J, García Gómez B, Medina Polo J, et al. Evaluation of current errors within the administration of phosphodiesterase-5 inhibitors after more than 10 years of use. Urology 2014; 83(6): 1334–8.CrossRefPubMed
25.
Zurück zum Zitat Ahn GJ, Yu JY, Choi SM, et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl. 2005; 28(5): 260–6.CrossRefPubMed Ahn GJ, Yu JY, Choi SM, et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl. 2005; 28(5): 260–6.CrossRefPubMed
26.
Zurück zum Zitat Bansal UK, Jones C, Fuller TW, et al. The Efficacy of Tadalafil Daily vs on Demand in the Treatment of Erectile Dysfunction: A Systematic Review and Meta-analysis. Urology 2017; https://doi.org/10.1016/j.urology.2017.08.031. Bansal UK, Jones C, Fuller TW, et al. The Efficacy of Tadalafil Daily vs on Demand in the Treatment of Erectile Dysfunction: A Systematic Review and Meta-analysis. Urology 2017; https://​doi.​org/​10.​1016/​j.​urology.​2017.​08.​031.​
27.
Zurück zum Zitat Osmonov DK, Jünemann KP, Bannowsky A. The „Kiel Concept“ of Long-Term Administration of Daily Low-Dose Sildenafil Initiated in the Immediate Post-Prostatectomy Period: Evaluation and Comparison With the International Literature on Penile Rehabilitation. Sex Med Rev. 2017; 5(3): 387–92.CrossRefPubMed Osmonov DK, Jünemann KP, Bannowsky A. The „Kiel Concept“ of Long-Term Administration of Daily Low-Dose Sildenafil Initiated in the Immediate Post-Prostatectomy Period: Evaluation and Comparison With the International Literature on Penile Rehabilitation. Sex Med Rev. 2017; 5(3): 387–92.CrossRefPubMed
28.
Zurück zum Zitat Ernst E, Pittler MH. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol. 1998; 159: 433–6.CrossRefPubMed Ernst E, Pittler MH. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol. 1998; 159: 433–6.CrossRefPubMed
29.
Zurück zum Zitat Riley AJ. Yohimbine in the treatment of erectile disorder. Br J Clin Pract. 1994; 48(3): 133–6.PubMed Riley AJ. Yohimbine in the treatment of erectile disorder. Br J Clin Pract. 1994; 48(3): 133–6.PubMed
30.
Zurück zum Zitat Reid K, Surridge DH, Morales A, et al. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet. 1987; 2(8556): 421–3.CrossRefPubMed Reid K, Surridge DH, Morales A, et al. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet. 1987; 2(8556): 421–3.CrossRefPubMed
31.
Zurück zum Zitat Melnik T, Soares BGO, Nasello AG. The evectiveness of psychological interventions for the treatment of erectile dysfunction: Systematic review and meta-analysis, Including comparisons to sildenafil treatment, intracavernosal injection, and vacuum Devices. J Sex Med. 2008; 5: 2562–74.CrossRefPubMed Melnik T, Soares BGO, Nasello AG. The evectiveness of psychological interventions for the treatment of erectile dysfunction: Systematic review and meta-analysis, Including comparisons to sildenafil treatment, intracavernosal injection, and vacuum Devices. J Sex Med. 2008; 5: 2562–74.CrossRefPubMed
32.
Zurück zum Zitat Hartmann U. Serie: Sexuelle Funktionsstörungen — Psychosomatische Aspekte bei Erektionsstörungen. Dtsch Arztebl. 200; 97(10): A-615/B-534/C-488. Hartmann U. Serie: Sexuelle Funktionsstörungen — Psychosomatische Aspekte bei Erektionsstörungen. Dtsch Arztebl. 200; 97(10): A-615/B-534/C-488.
33.
Zurück zum Zitat Graham P, Collins JP, Thijssen AM. Popularity of the vacuum erection device in male sexual dysfunction. Int J Impot Res. 1998; 10: S6. Graham P, Collins JP, Thijssen AM. Popularity of the vacuum erection device in male sexual dysfunction. Int J Impot Res. 1998; 10: S6.
34.
Zurück zum Zitat Porst H. Transurethral alprostadil with MUSE versus intracavernous alprostadil: A comparative study in 103 patients with erectile dysfunction. Int J of Impot Res. 1997; 9:187–92.CrossRef Porst H. Transurethral alprostadil with MUSE versus intracavernous alprostadil: A comparative study in 103 patients with erectile dysfunction. Int J of Impot Res. 1997; 9:187–92.CrossRef
35.
Zurück zum Zitat Raina R, Pahlajani G, Agarwal A, et al. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int. 2007; 100(6): 1317–21.CrossRefPubMed Raina R, Pahlajani G, Agarwal A, et al. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int. 2007; 100(6): 1317–21.CrossRefPubMed
36.
Zurück zum Zitat Urciuoli R, Cantisani TA, Carlini M, et al. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev. 2004; (2): CD001784. Urciuoli R, Cantisani TA, Carlini M, et al. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev. 2004; (2): CD001784.
37.
Zurück zum Zitat Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am. 1995; 22(4): 833–45.PubMed Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am. 1995; 22(4): 833–45.PubMed
38.
Zurück zum Zitat Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997; 336(1): 1–7.CrossRefPubMed Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997; 336(1): 1–7.CrossRefPubMed
39.
Zurück zum Zitat Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996; 334(14): 873–7.CrossRefPubMed Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996; 334(14): 873–7.CrossRefPubMed
40.
Zurück zum Zitat McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol. 1999; 162(6): 1992–7.CrossRefPubMed McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol. 1999; 162(6): 1992–7.CrossRefPubMed
41.
Zurück zum Zitat Wilson SK, Delk JR, Salem EA, et al. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med. 2007; 4: 1074–9.CrossRefPubMed Wilson SK, Delk JR, Salem EA, et al. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med. 2007; 4: 1074–9.CrossRefPubMed
42.
Zurück zum Zitat Henry GD, Donatucci CF, Conners W, et al. An Outcomes Analysis of over 200 Revision Surgeries for Penile Prosthesis Implantation: A Multicenter Study. J Sex Med. 2012; 9(1): 309–15.CrossRefPubMed Henry GD, Donatucci CF, Conners W, et al. An Outcomes Analysis of over 200 Revision Surgeries for Penile Prosthesis Implantation: A Multicenter Study. J Sex Med. 2012; 9(1): 309–15.CrossRefPubMed
43.
Zurück zum Zitat Mulcahy JJ, Wilson SK. Current use of penile implants in erectile dysfunction. Curr Urol Rep. 2006; 7(6): 485–9.CrossRefPubMed Mulcahy JJ, Wilson SK. Current use of penile implants in erectile dysfunction. Curr Urol Rep. 2006; 7(6): 485–9.CrossRefPubMed
44.
Zurück zum Zitat Marcon J, Stief CG, Trottmann M. Alterantive Therapieoptionen bei erektiler Dysfunktion. URO-NEWS 2016; 20 (10): 48–53.CrossRef Marcon J, Stief CG, Trottmann M. Alterantive Therapieoptionen bei erektiler Dysfunktion. URO-NEWS 2016; 20 (10): 48–53.CrossRef
45.
Zurück zum Zitat Vardi Y, Appel B, Jacob G, et al. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. 2010; 58(2): 243–8. Vardi Y, Appel B, Jacob G, et al. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. 2010; 58(2): 243–8.
46.
Zurück zum Zitat Lu Z, Lin G, Reed-Maldonado A, et al. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis.. 2017; 71 (2): 223–33. Lu Z, Lin G, Reed-Maldonado A, et al. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis.. 2017; 71 (2): 223–33.
47.
Zurück zum Zitat Fojecki GL, Tiessen S, Osther PJ, Effect of Low-Energy Linear Shockwave Therapy on Erectile Dysfunction-A Double-Blinded, Sham-Controlled, Randomized Clinical Trial. J Sex Med. 2017; 14 (1): 106–12.CrossRefPubMed Fojecki GL, Tiessen S, Osther PJ, Effect of Low-Energy Linear Shockwave Therapy on Erectile Dysfunction-A Double-Blinded, Sham-Controlled, Randomized Clinical Trial. J Sex Med. 2017; 14 (1): 106–12.CrossRefPubMed
Metadaten
Titel
Individuelle und multimodale Therapie nach Stufenschema
Erektile Dysfunktion — Update 2018
verfasst von
PD Dr. med. Matthias Trottmann
Publikationsdatum
02.04.2018
Verlag
Springer Medizin
Erschienen in
Uro-News / Ausgabe 4/2018
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI
https://doi.org/10.1007/s00092-018-1681-0

Weitere Artikel der Ausgabe 4/2018

Uro-News 4/2018 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.